Bioactive compounds: safety and efficacy

Hans-Konrad Biesalski, Lars Ove Dragsted, Ibrahim Elmadfa, Rolf Grossklaus, Michael Müller, Dieter Schrenk, Paul Walter, Peter Weber

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)


The efficacy and safety of bioactive compounds depend on a few known and unknown parameters. What is a physiologic dose and how can that dose be defined in cases of bioactive compounds with a poor knowledge of supply and distribution? What safety sets are needed? How can individual aspects such as polymorphisms or differences in absorption be considered? A group of experts tried to answer these and related questions during the 23rd Hohenheim Consensus Meeting at the University of Hohenheim in Stuttgart.
Original languageEnglish
Pages (from-to)1206-1211
Number of pages6
Issue number11-12
Publication statusPublished - Nov 2009


  • Biological Markers
  • Biological Products
  • Dietary Supplements
  • Drug Dosage Calculations
  • Humans
  • Intestinal Absorption
  • Polymorphism, Genetic

Cite this